28170 Neutralizing interleukin-13 increases skin microbial diversity: Results from a phase 3, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis
2021 ◽
Vol 85
(3)
◽
pp. AB177
Keyword(s):
Phase 3
◽